Triptans and migraine: advances in use, administration, formulation, and development.

摘要: Recent triptan development has focused on new administration methods and formulations, combination therapies, treatment in menstrually related migraines, novel serotonin receptor subtype agonists (5HTf). Areas covered: Clinical research to migraine was reviewed, analyzing EMBASE PUBMED data bases from 01/01/2011 06/29/2016, with a focus clinical trials of class 1 or 2 level evidence. There have been advances drug as well devices that aid ease use, increase efficacy, decrease adverse reactions. Some agents similar less efficacy compared previous generic formulations. New action at the 5HTf subtype, avoid vascular side effects classic 5Ht1b/d agonists, however reactions may limit their clinic use. Long half-life triptans, frovatriptan naratriptan, do appear good benefit menstral migraine. Expert opinion: can offer some advantages therapy patient preferences, but much higher cost individual agents. In coming years, high limiting ADRs are welcomed, this regard 5HT1b/d triptans already established.